Popular Articles
Teeth Whitening Products

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (Mesalamine) Delayed-Release Tablets For Moderately Active Ulcerative Colitis
Procter & Gamble Pharmaceuticals (P&GP) announced the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these tougher flares of moderately active UC. Asacol HD was approved by the U.S. Food and Drug Administration (FDA) based on evaluations from the ASCEND studies [Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA (4.8 g/day 800 mg tablet)].
generic viagra online
Revance Therapeutics Announces Efficacy Of Topical Botulinum Toxin Type A For The Treatment Of Facial Wrinkles
Revance Therapeutics, Inc. ("Revance") announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow"s feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints.
News of the day
Provectus Completes Patient Accrual In Phase 2 Trial Of PV-10 For Metastatic Melanoma
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company has completed patient accrual and initial PV-10 treatment in its Phase 2 trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.
Public Health

Study Estimates Cost Added To Private Health Insurance Premiums To Cover Uncompensated Care

The average U.S. family and their employers paid an additional $1,017 in health care premiums in 2008 to pay for care of the uninsured, according to a study released on Thursday by Families USA, USA Today reports (Kim, USA Today, 5/28). According to the study, which examined federal data, the uninsured received $116 billion in health care from hospitals, physicians and other providers in 2008 and paid 37% of that amount. Government programs and charities covered an additional 26%, which left another 37%, or about $43 billion, unpaid. The study then estimated how those costs are when spread across the insured through higher premiums, the study found. According to the study, prepared by the actuarial firm Milliman, the average additional amount paid under private coverage for single individuals was about $370 per year (Werner, AP/Austin American-Statesman, 5/28). Families USA Executive Director Ron Pollack said, "This is a hidden tax on all insurance premiums, whether it is paid by business for their work or by families when they purchase their own coverage" (USA Today, 5/28).The study is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):